Richard Turnage
Concepts (472)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Intestines | 18 | 1998 | 204 | 1.710 |
Why?
| Reperfusion Injury | 17 | 2005 | 118 | 1.620 |
Why?
| General Surgery | 4 | 2014 | 113 | 0.940 |
Why?
| Capillary Permeability | 7 | 2003 | 40 | 0.750 |
Why?
| Lung | 13 | 2003 | 507 | 0.710 |
Why?
| Tumor Necrosis Factor-alpha | 5 | 2003 | 434 | 0.590 |
Why?
| Rats, Sprague-Dawley | 27 | 2005 | 1663 | 0.560 |
Why?
| Ischemia | 7 | 1998 | 177 | 0.560 |
Why?
| Rats | 32 | 2005 | 3415 | 0.560 |
Why?
| Keratinocytes | 3 | 2001 | 96 | 0.520 |
Why?
| Thromboxane A2 | 4 | 2002 | 23 | 0.510 |
Why?
| Pulmonary Circulation | 6 | 2003 | 36 | 0.510 |
Why?
| Private Practice | 1 | 2014 | 12 | 0.500 |
Why?
| Financial Management | 1 | 2014 | 13 | 0.500 |
Why?
| Endothelium, Vascular | 7 | 2003 | 288 | 0.490 |
Why?
| Internship and Residency | 3 | 2014 | 501 | 0.470 |
Why?
| Dinoprostone | 7 | 2000 | 55 | 0.460 |
Why?
| Education, Medical, Graduate | 2 | 2014 | 225 | 0.450 |
Why?
| Microcirculation | 8 | 2006 | 89 | 0.450 |
Why?
| Nitric Oxide | 4 | 2006 | 298 | 0.430 |
Why?
| Pulmonary Edema | 4 | 1998 | 17 | 0.410 |
Why?
| Epoprostenol | 8 | 2000 | 27 | 0.390 |
Why?
| Oxidants | 3 | 2006 | 64 | 0.390 |
Why?
| Burns | 3 | 2003 | 170 | 0.390 |
Why?
| Neutrophils | 5 | 2000 | 154 | 0.390 |
Why?
| Splanchnic Circulation | 5 | 1998 | 43 | 0.380 |
Why?
| Protein-Tyrosine Kinases | 2 | 2001 | 101 | 0.370 |
Why?
| Animals | 40 | 2006 | 14385 | 0.370 |
Why?
| Liability, Legal | 1 | 2009 | 13 | 0.340 |
Why?
| Insurance Claim Review | 1 | 2009 | 28 | 0.340 |
Why?
| Malpractice | 1 | 2009 | 16 | 0.340 |
Why?
| Medical Errors | 1 | 2009 | 34 | 0.340 |
Why?
| Nitric Oxide Synthase | 5 | 2006 | 102 | 0.330 |
Why?
| Cell Membrane Permeability | 2 | 2006 | 28 | 0.330 |
Why?
| Reperfusion | 3 | 1996 | 15 | 0.310 |
Why?
| Endothelial Cells | 2 | 2006 | 294 | 0.290 |
Why?
| Cadherins | 2 | 2002 | 72 | 0.260 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2003 | 169 | 0.260 |
Why?
| Attitude of Health Personnel | 1 | 2009 | 397 | 0.260 |
Why?
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2002 | 7 | 0.240 |
Why?
| Duodenal Ulcer | 1 | 2003 | 13 | 0.240 |
Why?
| Gelsolin | 1 | 2003 | 2 | 0.230 |
Why?
| Liver | 5 | 2004 | 1225 | 0.230 |
Why?
| Insulin | 1 | 2006 | 510 | 0.220 |
Why?
| Cells, Cultured | 8 | 2006 | 1737 | 0.220 |
Why?
| Male | 38 | 2011 | 27312 | 0.220 |
Why?
| Thromboxane B2 | 4 | 1998 | 11 | 0.220 |
Why?
| Colonic Neoplasms | 2 | 2003 | 164 | 0.210 |
Why?
| Pneumonia | 1 | 2003 | 129 | 0.210 |
Why?
| Humans | 42 | 2017 | 54246 | 0.210 |
Why?
| Antigens, CD | 3 | 2002 | 242 | 0.210 |
Why?
| Gastroesophageal Reflux | 3 | 1991 | 49 | 0.200 |
Why?
| Positron-Emission Tomography | 3 | 2010 | 322 | 0.200 |
Why?
| Neoplasm Recurrence, Local | 4 | 2007 | 644 | 0.190 |
Why?
| Neutrophil Activation | 1 | 2000 | 10 | 0.190 |
Why?
| Hernia, Inguinal | 2 | 2000 | 19 | 0.190 |
Why?
| Cytoskeleton | 1 | 2000 | 50 | 0.190 |
Why?
| Skin | 2 | 2003 | 469 | 0.190 |
Why?
| Prostaglandins | 1 | 2000 | 19 | 0.190 |
Why?
| Brain Edema | 3 | 2005 | 39 | 0.180 |
Why?
| Kidney | 4 | 2002 | 820 | 0.180 |
Why?
| Hernia, Ventral | 1 | 2000 | 10 | 0.180 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2000 | 63 | 0.180 |
Why?
| Actins | 1 | 2000 | 132 | 0.180 |
Why?
| Surgical Wound Dehiscence | 1 | 2000 | 21 | 0.180 |
Why?
| Critical Pathways | 1 | 2000 | 36 | 0.180 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 1999 | 55 | 0.170 |
Why?
| Wound Healing | 1 | 2001 | 228 | 0.170 |
Why?
| Population Surveillance | 1 | 2000 | 183 | 0.170 |
Why?
| Thyroid Neoplasms | 2 | 2015 | 162 | 0.170 |
Why?
| Lipopolysaccharides | 1 | 1999 | 199 | 0.170 |
Why?
| Resuscitation | 2 | 1996 | 83 | 0.170 |
Why?
| Pulmonary Artery | 1 | 2000 | 151 | 0.160 |
Why?
| Lung Injury | 4 | 2003 | 25 | 0.160 |
Why?
| Educational Measurement | 1 | 2000 | 232 | 0.160 |
Why?
| Diabetes Mellitus, Experimental | 1 | 1999 | 140 | 0.160 |
Why?
| Signal Transduction | 3 | 2015 | 1753 | 0.160 |
Why?
| Macrophage Activation | 1 | 1998 | 29 | 0.160 |
Why?
| Macrophages, Alveolar | 1 | 1998 | 26 | 0.160 |
Why?
| Students, Medical | 1 | 2000 | 173 | 0.160 |
Why?
| Interleukin-2 | 1 | 2017 | 75 | 0.150 |
Why?
| Anal Gland Neoplasms | 1 | 1997 | 1 | 0.150 |
Why?
| Perfusion | 4 | 2002 | 40 | 0.150 |
Why?
| Colorectal Neoplasms | 1 | 2000 | 235 | 0.150 |
Why?
| Breast Neoplasms | 4 | 2007 | 1248 | 0.150 |
Why?
| Incidence | 5 | 2006 | 1082 | 0.140 |
Why?
| Calcineurin | 1 | 2017 | 70 | 0.140 |
Why?
| Eukaryotic Initiation Factor-4E | 2 | 2006 | 8 | 0.140 |
Why?
| Portal Vein | 1 | 1996 | 30 | 0.140 |
Why?
| Hepatic Artery | 1 | 1996 | 25 | 0.140 |
Why?
| Amino Acid Oxidoreductases | 1 | 1995 | 7 | 0.140 |
Why?
| Shock, Hemorrhagic | 1 | 1995 | 10 | 0.140 |
Why?
| Promoter Regions, Genetic | 1 | 1998 | 520 | 0.130 |
Why?
| Apolipoproteins A | 2 | 2005 | 2 | 0.130 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2015 | 27 | 0.130 |
Why?
| DNA-Activated Protein Kinase | 1 | 2015 | 23 | 0.130 |
Why?
| Hydroxyl Radical | 1 | 1994 | 10 | 0.130 |
Why?
| Recurrence | 4 | 2003 | 690 | 0.130 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2015 | 35 | 0.130 |
Why?
| Phosphorylation | 5 | 2017 | 614 | 0.130 |
Why?
| Middle Aged | 15 | 2011 | 13070 | 0.130 |
Why?
| Plasma Volume | 1 | 1994 | 9 | 0.130 |
Why?
| Complement Activation | 1 | 1994 | 43 | 0.130 |
Why?
| Contract Services | 1 | 2014 | 15 | 0.130 |
Why?
| Electrolytes | 1 | 1994 | 25 | 0.130 |
Why?
| Gastric Fundus | 2 | 1991 | 8 | 0.120 |
Why?
| Hemorrhage | 1 | 1996 | 208 | 0.120 |
Why?
| Endotoxins | 1 | 1994 | 37 | 0.120 |
Why?
| Physician Assistants | 1 | 2014 | 20 | 0.120 |
Why?
| Multiple Trauma | 1 | 1994 | 34 | 0.120 |
Why?
| Risk Management | 1 | 2014 | 34 | 0.120 |
Why?
| Imidazoles | 3 | 2006 | 142 | 0.120 |
Why?
| Blood Volume | 1 | 1994 | 69 | 0.120 |
Why?
| Enzyme Inhibitors | 4 | 2006 | 446 | 0.120 |
Why?
| Piperidines | 2 | 2005 | 103 | 0.120 |
Why?
| Polyethylene Glycols | 1 | 1994 | 106 | 0.120 |
Why?
| Postoperative Complications | 4 | 2003 | 1033 | 0.120 |
Why?
| Esophagus | 2 | 1991 | 79 | 0.120 |
Why?
| Nuclear Proteins | 1 | 2015 | 252 | 0.120 |
Why?
| Disease Models, Animal | 7 | 2004 | 1639 | 0.110 |
Why?
| Renal Circulation | 4 | 1997 | 82 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 4 | 2006 | 1476 | 0.110 |
Why?
| Adenocarcinoma | 1 | 1997 | 428 | 0.110 |
Why?
| Time Factors | 6 | 2006 | 3212 | 0.110 |
Why?
| Proteomics | 1 | 2015 | 343 | 0.110 |
Why?
| Heart Arrest | 2 | 2005 | 159 | 0.110 |
Why?
| Blood Pressure | 5 | 2000 | 586 | 0.110 |
Why?
| Intramolecular Oxidoreductases | 3 | 1996 | 17 | 0.100 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2001 | 20 | 0.100 |
Why?
| Focal Adhesion Kinase 1 | 2 | 2001 | 15 | 0.100 |
Why?
| Curriculum | 1 | 2014 | 429 | 0.100 |
Why?
| Abdominal Pain | 1 | 2011 | 77 | 0.100 |
Why?
| Enzyme Activation | 2 | 2002 | 329 | 0.100 |
Why?
| Malabsorption Syndromes | 1 | 1990 | 9 | 0.090 |
Why?
| Texas | 2 | 2000 | 160 | 0.090 |
Why?
| Vascular Resistance | 2 | 2000 | 60 | 0.090 |
Why?
| Ileum | 1 | 1990 | 102 | 0.090 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 541 | 0.090 |
Why?
| Risk Factors | 6 | 2007 | 3930 | 0.090 |
Why?
| Pancreatic Cyst | 1 | 1988 | 13 | 0.080 |
Why?
| Glutathione | 2 | 2005 | 330 | 0.080 |
Why?
| Random Allocation | 3 | 2004 | 312 | 0.080 |
Why?
| Cysts | 1 | 1988 | 50 | 0.080 |
Why?
| Recombinant Proteins | 3 | 2005 | 569 | 0.080 |
Why?
| Receptors, CXCR4 | 1 | 2007 | 31 | 0.080 |
Why?
| Liver Diseases | 1 | 1988 | 87 | 0.080 |
Why?
| Nitric Oxide Donors | 2 | 2004 | 12 | 0.080 |
Why?
| Follow-Up Studies | 4 | 2005 | 2387 | 0.080 |
Why?
| Receptor, erbB-2 | 1 | 2007 | 79 | 0.070 |
Why?
| Carcinoma, Hepatocellular | 1 | 2010 | 203 | 0.070 |
Why?
| Quality of Health Care | 1 | 2009 | 222 | 0.070 |
Why?
| Eicosanoids | 2 | 1997 | 19 | 0.070 |
Why?
| Aged | 7 | 2011 | 10041 | 0.070 |
Why?
| Female | 14 | 2011 | 28418 | 0.070 |
Why?
| Analysis of Variance | 2 | 2000 | 635 | 0.070 |
Why?
| Rabbits | 2 | 2006 | 425 | 0.070 |
Why?
| Carcinoma, Lobular | 1 | 2006 | 32 | 0.070 |
Why?
| Retrospective Studies | 6 | 2011 | 6432 | 0.070 |
Why?
| Ornithine | 1 | 2006 | 16 | 0.070 |
Why?
| Colectomy | 2 | 2000 | 33 | 0.070 |
Why?
| Cyclic N-Oxides | 1 | 2006 | 15 | 0.070 |
Why?
| Chromones | 1 | 2006 | 16 | 0.070 |
Why?
| Electric Impedance | 1 | 2006 | 43 | 0.070 |
Why?
| Free Radical Scavengers | 1 | 2006 | 35 | 0.070 |
Why?
| Osmolar Concentration | 1 | 2006 | 83 | 0.070 |
Why?
| Culture Media | 1 | 2006 | 100 | 0.070 |
Why?
| Pancreatic Neoplasms | 1 | 1988 | 234 | 0.070 |
Why?
| Liver Neoplasms | 1 | 2010 | 352 | 0.070 |
Why?
| Morpholines | 1 | 2006 | 64 | 0.070 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2006 | 96 | 0.070 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2003 | 99 | 0.070 |
Why?
| Hydrogen Peroxide | 1 | 2006 | 142 | 0.070 |
Why?
| Chromatography | 1 | 2005 | 16 | 0.070 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2006 | 230 | 0.060 |
Why?
| Treatment Outcome | 5 | 2011 | 5604 | 0.060 |
Why?
| Indomethacin | 3 | 2000 | 40 | 0.060 |
Why?
| Cell Separation | 1 | 2005 | 107 | 0.060 |
Why?
| Pyridines | 2 | 2003 | 137 | 0.060 |
Why?
| Umbilical Veins | 2 | 2002 | 23 | 0.060 |
Why?
| Asphyxia | 1 | 2004 | 11 | 0.060 |
Why?
| Neoplasm Staging | 4 | 2010 | 806 | 0.060 |
Why?
| Nitroso Compounds | 1 | 2004 | 5 | 0.060 |
Why?
| Disease-Free Survival | 2 | 2007 | 485 | 0.060 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2004 | 51 | 0.060 |
Why?
| United States | 2 | 2009 | 5200 | 0.060 |
Why?
| Colitis | 1 | 2004 | 52 | 0.060 |
Why?
| Vagotomy | 1 | 2003 | 7 | 0.060 |
Why?
| rho GTP-Binding Proteins | 1 | 2003 | 6 | 0.060 |
Why?
| Referral and Consultation | 1 | 2006 | 307 | 0.060 |
Why?
| Vitamin D-Binding Protein | 1 | 2003 | 4 | 0.060 |
Why?
| Mesenteric Arteries | 3 | 1998 | 45 | 0.060 |
Why?
| Glucose | 1 | 2006 | 366 | 0.060 |
Why?
| Hematocrit | 1 | 2003 | 51 | 0.060 |
Why?
| Lymph Nodes | 1 | 2005 | 284 | 0.060 |
Why?
| Carbon Dioxide | 1 | 2003 | 102 | 0.060 |
Why?
| Epithelial Cells | 2 | 2004 | 255 | 0.060 |
Why?
| Myocardial Reperfusion Injury | 1 | 2003 | 49 | 0.060 |
Why?
| Prognosis | 3 | 2007 | 2118 | 0.060 |
Why?
| Tissue Donors | 1 | 2003 | 110 | 0.060 |
Why?
| Aorta | 4 | 1998 | 177 | 0.060 |
Why?
| Anti-Inflammatory Agents | 1 | 2004 | 175 | 0.060 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2003 | 83 | 0.060 |
Why?
| Accidents, Traffic | 1 | 2003 | 117 | 0.060 |
Why?
| Dinoprost | 2 | 2000 | 12 | 0.060 |
Why?
| Blood Proteins | 1 | 2003 | 100 | 0.060 |
Why?
| Fluorescein-5-isothiocyanate | 1 | 2002 | 11 | 0.060 |
Why?
| Receptors, Angiotensin | 1 | 2002 | 12 | 0.060 |
Why?
| Helicobacter pylori | 1 | 2003 | 74 | 0.060 |
Why?
| Receptors, Thromboxane | 1 | 2002 | 12 | 0.060 |
Why?
| Dextrans | 1 | 2002 | 20 | 0.050 |
Why?
| Helicobacter Infections | 1 | 2003 | 73 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2003 | 231 | 0.050 |
Why?
| Hypertension, Renovascular | 1 | 2002 | 16 | 0.050 |
Why?
| Emergencies | 1 | 2003 | 92 | 0.050 |
Why?
| Adrenal Glands | 1 | 2002 | 37 | 0.050 |
Why?
| Brain Ischemia | 1 | 2004 | 169 | 0.050 |
Why?
| Bronchi | 1 | 2002 | 51 | 0.050 |
Why?
| Myocardial Ischemia | 1 | 2003 | 127 | 0.050 |
Why?
| Interleukin-1 | 1 | 2002 | 107 | 0.050 |
Why?
| Adult | 8 | 2011 | 14182 | 0.050 |
Why?
| Renin-Angiotensin System | 1 | 2002 | 64 | 0.050 |
Why?
| Flavonoids | 1 | 2002 | 62 | 0.050 |
Why?
| Survival Rate | 2 | 2005 | 951 | 0.050 |
Why?
| Drug Synergism | 1 | 2002 | 171 | 0.050 |
Why?
| Tyrosine | 1 | 2002 | 137 | 0.050 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 142 | 0.050 |
Why?
| Mice | 4 | 2006 | 6413 | 0.050 |
Why?
| Rats, Wistar | 1 | 2002 | 237 | 0.050 |
Why?
| Isomerases | 3 | 1996 | 5 | 0.050 |
Why?
| Capillaries | 2 | 1998 | 58 | 0.050 |
Why?
| Intestinal Mucosa | 3 | 2004 | 259 | 0.050 |
Why?
| Breast Neoplasms, Male | 1 | 2001 | 6 | 0.050 |
Why?
| Gynecomastia | 1 | 2001 | 5 | 0.050 |
Why?
| Enzyme Induction | 1 | 2001 | 80 | 0.050 |
Why?
| Organ Culture Techniques | 1 | 2001 | 53 | 0.050 |
Why?
| Cell Membrane | 1 | 2002 | 278 | 0.050 |
Why?
| Vasodilator Agents | 2 | 2005 | 111 | 0.050 |
Why?
| Superoxides | 2 | 1998 | 61 | 0.050 |
Why?
| Chronic Disease | 2 | 2002 | 612 | 0.050 |
Why?
| Alanine Transaminase | 2 | 2004 | 151 | 0.050 |
Why?
| Mammography | 1 | 2001 | 95 | 0.050 |
Why?
| Reference Values | 2 | 2004 | 354 | 0.050 |
Why?
| Documentation | 1 | 2000 | 32 | 0.050 |
Why?
| Myocardium | 1 | 2003 | 441 | 0.050 |
Why?
| Integrins | 1 | 2000 | 36 | 0.050 |
Why?
| Up-Regulation | 1 | 2002 | 508 | 0.050 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2003 | 596 | 0.050 |
Why?
| Extravascular Lung Water | 1 | 1999 | 2 | 0.050 |
Why?
| Cytochrome P-450 Enzyme System | 3 | 1996 | 192 | 0.050 |
Why?
| Sex Distribution | 1 | 2000 | 158 | 0.050 |
Why?
| Age Distribution | 1 | 2000 | 198 | 0.050 |
Why?
| Pulmonary Alveoli | 1 | 1999 | 20 | 0.050 |
Why?
| Neutrophil Infiltration | 1 | 1999 | 29 | 0.050 |
Why?
| Cell Movement | 1 | 2001 | 271 | 0.050 |
Why?
| Oxidative Stress | 1 | 2005 | 958 | 0.040 |
Why?
| Rats, Zucker | 1 | 1999 | 73 | 0.040 |
Why?
| Interpersonal Relations | 1 | 2000 | 117 | 0.040 |
Why?
| Colon | 2 | 2004 | 110 | 0.040 |
Why?
| Academic Medical Centers | 1 | 2000 | 141 | 0.040 |
Why?
| Interprofessional Relations | 1 | 2000 | 97 | 0.040 |
Why?
| Microspheres | 2 | 1996 | 34 | 0.040 |
Why?
| Faculty, Medical | 1 | 2000 | 100 | 0.040 |
Why?
| Glutathione Disulfide | 2 | 2005 | 45 | 0.040 |
Why?
| 6-Ketoprostaglandin F1 alpha | 2 | 1996 | 8 | 0.040 |
Why?
| NG-Nitroarginine Methyl Ester | 2 | 1996 | 21 | 0.040 |
Why?
| Apoptosis | 1 | 2005 | 1300 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2000 | 291 | 0.040 |
Why?
| Regional Blood Flow | 2 | 1996 | 121 | 0.040 |
Why?
| Body Fluids | 1 | 1998 | 26 | 0.040 |
Why?
| Collagen | 1 | 2000 | 223 | 0.040 |
Why?
| Specific Pathogen-Free Organisms | 1 | 1998 | 15 | 0.040 |
Why?
| Sensitivity and Specificity | 3 | 2010 | 923 | 0.040 |
Why?
| Wounds, Stab | 1 | 1998 | 8 | 0.040 |
Why?
| Sex | 1 | 1998 | 2 | 0.040 |
Why?
| Student Dropouts | 1 | 1998 | 3 | 0.040 |
Why?
| Integrin alphaV | 1 | 1998 | 3 | 0.040 |
Why?
| Sequence Homology | 1 | 1998 | 21 | 0.040 |
Why?
| Luciferases | 1 | 1998 | 57 | 0.040 |
Why?
| Epidermal Growth Factor | 1 | 1998 | 38 | 0.040 |
Why?
| Glucuronidase | 1 | 1998 | 48 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 92 | 0.040 |
Why?
| Proteins | 2 | 1998 | 376 | 0.040 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 1988 | 87 | 0.040 |
Why?
| Microscopy, Fluorescence | 1 | 1998 | 198 | 0.040 |
Why?
| Aortic Aneurysm | 1 | 1998 | 29 | 0.040 |
Why?
| Lysosomes | 1 | 1998 | 91 | 0.040 |
Why?
| Blood Coagulation | 1 | 1998 | 69 | 0.040 |
Why?
| NFATC Transcription Factors | 1 | 2017 | 20 | 0.040 |
Why?
| Jurkat Cells | 1 | 2017 | 34 | 0.040 |
Why?
| DNA, Single-Stranded | 1 | 1998 | 73 | 0.040 |
Why?
| Active Transport, Cell Nucleus | 1 | 2017 | 45 | 0.040 |
Why?
| Reoperation | 1 | 2000 | 454 | 0.040 |
Why?
| Protein Stability | 1 | 2017 | 44 | 0.040 |
Why?
| Registries | 1 | 2000 | 553 | 0.040 |
Why?
| Antineoplastic Agents | 2 | 2003 | 1300 | 0.040 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 866 | 0.040 |
Why?
| Transfection | 1 | 1998 | 399 | 0.040 |
Why?
| Arginine | 2 | 1996 | 182 | 0.040 |
Why?
| Radiotherapy, Adjuvant | 1 | 1997 | 66 | 0.040 |
Why?
| Transcriptional Activation | 1 | 2017 | 134 | 0.040 |
Why?
| Permeability | 1 | 1997 | 87 | 0.040 |
Why?
| Binding Sites | 1 | 1998 | 440 | 0.040 |
Why?
| Fluorodeoxyglucose F18 | 2 | 2010 | 205 | 0.040 |
Why?
| Radiopharmaceuticals | 2 | 2010 | 238 | 0.040 |
Why?
| Chemotherapy, Adjuvant | 1 | 1997 | 119 | 0.040 |
Why?
| Gene Deletion | 1 | 1998 | 293 | 0.040 |
Why?
| Base Sequence | 1 | 1998 | 719 | 0.040 |
Why?
| Oligopeptides | 1 | 2017 | 95 | 0.040 |
Why?
| Hemodynamics | 3 | 2004 | 290 | 0.040 |
Why?
| Parenteral Nutrition, Total | 1 | 1996 | 26 | 0.040 |
Why?
| Multiple Myeloma | 1 | 2011 | 3035 | 0.040 |
Why?
| Ruthenium Radioisotopes | 1 | 1996 | 2 | 0.040 |
Why?
| Cesium Radioisotopes | 1 | 1996 | 5 | 0.040 |
Why?
| Molecular Sequence Data | 1 | 1998 | 980 | 0.040 |
Why?
| Ultrasonography | 2 | 1988 | 480 | 0.040 |
Why?
| Brain | 1 | 2005 | 1387 | 0.030 |
Why?
| Protein Processing, Post-Translational | 1 | 2017 | 183 | 0.030 |
Why?
| Age Factors | 1 | 2000 | 1195 | 0.030 |
Why?
| Evans Blue | 1 | 1995 | 3 | 0.030 |
Why?
| Platelet Activating Factor | 1 | 1995 | 3 | 0.030 |
Why?
| Mesenteric Artery, Superior | 1 | 1995 | 10 | 0.030 |
Why?
| Prospective Studies | 3 | 2007 | 2604 | 0.030 |
Why?
| Gallbladder | 1 | 1995 | 24 | 0.030 |
Why?
| Hospitalization | 1 | 2000 | 705 | 0.030 |
Why?
| Cohort Studies | 1 | 2000 | 1543 | 0.030 |
Why?
| Sepsis | 1 | 1998 | 251 | 0.030 |
Why?
| Adenosine Triphosphate | 2 | 1996 | 242 | 0.030 |
Why?
| Complement C5a | 1 | 1994 | 4 | 0.030 |
Why?
| Chemotactic Factors | 1 | 1994 | 8 | 0.030 |
Why?
| Deferoxamine | 1 | 1994 | 12 | 0.030 |
Why?
| Thiourea | 1 | 1994 | 11 | 0.030 |
Why?
| Aged, 80 and over | 3 | 2011 | 3429 | 0.030 |
Why?
| Hospital Mortality | 2 | 2011 | 465 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 1996 | 140 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 2011 | 1136 | 0.030 |
Why?
| DNA-Binding Proteins | 1 | 1998 | 462 | 0.030 |
Why?
| Serum Albumin, Radio-Iodinated | 1 | 1994 | 1 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 1997 | 692 | 0.030 |
Why?
| Therapeutic Irrigation | 1 | 1994 | 27 | 0.030 |
Why?
| Cell Differentiation | 2 | 2010 | 720 | 0.030 |
Why?
| Gene Expression | 1 | 2017 | 664 | 0.030 |
Why?
| Polymyxin B | 1 | 1994 | 5 | 0.030 |
Why?
| Complement System Proteins | 1 | 1994 | 55 | 0.030 |
Why?
| Estrogens | 1 | 1996 | 244 | 0.030 |
Why?
| Length of Stay | 2 | 2011 | 683 | 0.030 |
Why?
| Drug Tolerance | 1 | 1994 | 60 | 0.030 |
Why?
| Tomography, X-Ray Computed | 3 | 1988 | 1213 | 0.030 |
Why?
| Child, Preschool | 3 | 1991 | 4146 | 0.030 |
Why?
| Indoles | 1 | 2015 | 289 | 0.030 |
Why?
| Models, Biological | 1 | 1996 | 823 | 0.030 |
Why?
| Lipid Peroxides | 1 | 1991 | 15 | 0.030 |
Why?
| Enterocolitis, Neutropenic | 1 | 2011 | 7 | 0.030 |
Why?
| Ileus | 1 | 2011 | 16 | 0.030 |
Why?
| Infant | 2 | 1991 | 3817 | 0.030 |
Why?
| Predictive Value of Tests | 2 | 2007 | 1048 | 0.020 |
Why?
| Cytokines | 1 | 1994 | 676 | 0.020 |
Why?
| Cell Line, Tumor | 1 | 2015 | 1550 | 0.020 |
Why?
| Enteral Nutrition | 1 | 1991 | 136 | 0.020 |
Why?
| Postoperative Care | 1 | 1991 | 121 | 0.020 |
Why?
| Gastrointestinal Transit | 1 | 1990 | 4 | 0.020 |
Why?
| Enema | 1 | 1990 | 8 | 0.020 |
Why?
| Barium Sulfate | 1 | 1990 | 13 | 0.020 |
Why?
| Adenomatous Polyposis Coli | 1 | 1990 | 8 | 0.020 |
Why?
| Patient Transfer | 1 | 2011 | 103 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 2 | 2003 | 194 | 0.020 |
Why?
| alpha-Fetoproteins | 1 | 2010 | 15 | 0.020 |
Why?
| Intestinal Absorption | 1 | 1990 | 60 | 0.020 |
Why?
| Blotting, Western | 2 | 2005 | 683 | 0.020 |
Why?
| Dogs | 1 | 1990 | 217 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 514 | 0.020 |
Why?
| Colitis, Ulcerative | 1 | 1990 | 52 | 0.020 |
Why?
| Diarrhea | 1 | 1990 | 90 | 0.020 |
Why?
| Evaluation Studies as Topic | 1 | 1989 | 107 | 0.020 |
Why?
| Child | 3 | 1991 | 7337 | 0.020 |
Why?
| Patient Discharge | 1 | 2011 | 353 | 0.020 |
Why?
| Survival Analysis | 2 | 2003 | 735 | 0.020 |
Why?
| Weight Gain | 1 | 1990 | 243 | 0.020 |
Why?
| Angiography | 1 | 1988 | 147 | 0.020 |
Why?
| Mice, Inbred C57BL | 2 | 2004 | 1999 | 0.020 |
Why?
| Adolescent | 2 | 1991 | 6885 | 0.020 |
Why?
| Intraoperative Complications | 1 | 1989 | 125 | 0.020 |
Why?
| Neoplasms | 1 | 1998 | 1315 | 0.020 |
Why?
| Aorta, Abdominal | 2 | 1998 | 45 | 0.020 |
Why?
| Pyloric Antrum | 1 | 1986 | 9 | 0.020 |
Why?
| Cytomegalovirus Infections | 1 | 1986 | 46 | 0.020 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 1986 | 66 | 0.020 |
Why?
| Prostaglandin-Endoperoxide Synthases | 2 | 1996 | 26 | 0.020 |
Why?
| Mastectomy, Extended Radical | 1 | 2005 | 1 | 0.020 |
Why?
| tert-Butylhydroperoxide | 1 | 2005 | 6 | 0.020 |
Why?
| Glucosephosphate Dehydrogenase | 1 | 2005 | 7 | 0.020 |
Why?
| Apolipoprotein A-I | 1 | 2005 | 8 | 0.020 |
Why?
| PC12 Cells | 1 | 2005 | 31 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 124 | 0.020 |
Why?
| Biopsy, Fine-Needle | 1 | 2006 | 116 | 0.020 |
Why?
| Thioglycolates | 1 | 2005 | 6 | 0.020 |
Why?
| Cell Size | 1 | 2005 | 45 | 0.020 |
Why?
| Mitosis | 1 | 2005 | 106 | 0.020 |
Why?
| Dextran Sulfate | 1 | 2004 | 10 | 0.020 |
Why?
| Platelet Adhesiveness | 1 | 2004 | 13 | 0.020 |
Why?
| Indicators and Reagents | 1 | 2004 | 42 | 0.020 |
Why?
| Heart Arrest, Induced | 1 | 2004 | 5 | 0.020 |
Why?
| P-Selectin | 1 | 2004 | 33 | 0.020 |
Why?
| Cell Count | 1 | 2005 | 181 | 0.020 |
Why?
| Polyamines | 1 | 2004 | 10 | 0.020 |
Why?
| Lymphatic Metastasis | 1 | 2005 | 256 | 0.020 |
Why?
| Disease Progression | 1 | 2007 | 913 | 0.020 |
Why?
| Extracorporeal Circulation | 1 | 2003 | 11 | 0.020 |
Why?
| Blood Gas Analysis | 1 | 2003 | 32 | 0.020 |
Why?
| Leukocytes | 1 | 2004 | 85 | 0.020 |
Why?
| Aspartate Aminotransferases | 1 | 2004 | 57 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2005 | 382 | 0.020 |
Why?
| Decanoic Acids | 1 | 2003 | 1 | 0.010 |
Why?
| Alkenes | 1 | 2003 | 3 | 0.010 |
Why?
| Hydroxy Acids | 1 | 2003 | 8 | 0.010 |
Why?
| Probability | 1 | 2004 | 176 | 0.010 |
Why?
| Mice, Inbred NOD | 1 | 2004 | 99 | 0.010 |
Why?
| ADP Ribose Transferases | 1 | 2003 | 5 | 0.010 |
Why?
| Botulinum Toxins | 1 | 2003 | 5 | 0.010 |
Why?
| Amides | 1 | 2003 | 43 | 0.010 |
Why?
| Down-Regulation | 1 | 2005 | 388 | 0.010 |
Why?
| Mice, Inbred Strains | 1 | 2003 | 198 | 0.010 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2003 | 84 | 0.010 |
Why?
| Cattle | 1 | 2003 | 224 | 0.010 |
Why?
| Autocrine Communication | 1 | 2002 | 10 | 0.010 |
Why?
| Radioimmunoassay | 1 | 2002 | 41 | 0.010 |
Why?
| Cardiopulmonary Resuscitation | 1 | 2004 | 137 | 0.010 |
Why?
| Statistics, Nonparametric | 1 | 2003 | 232 | 0.010 |
Why?
| src-Family Kinases | 1 | 2002 | 54 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2006 | 1304 | 0.010 |
Why?
| Kidney Tubules, Proximal | 1 | 2002 | 119 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2003 | 656 | 0.010 |
Why?
| Mice, Knockout | 1 | 2004 | 926 | 0.010 |
Why?
| Angiotensin II | 1 | 2002 | 166 | 0.010 |
Why?
| Pyrimidines | 1 | 2002 | 196 | 0.010 |
Why?
| Odds Ratio | 1 | 2003 | 604 | 0.010 |
Why?
| Heart | 1 | 2003 | 360 | 0.010 |
Why?
| Echocardiography | 1 | 2003 | 392 | 0.010 |
Why?
| Cell Line | 1 | 2003 | 1153 | 0.010 |
Why?
| Inflammation | 1 | 2004 | 674 | 0.010 |
Why?
| Myocardial Infarction | 1 | 2003 | 424 | 0.010 |
Why?
| Case-Control Studies | 1 | 2003 | 1228 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2002 | 1089 | 0.010 |
Why?
| Ligation | 1 | 1998 | 64 | 0.010 |
Why?
| Cecum | 1 | 1998 | 72 | 0.010 |
Why?
| Anastomosis, Surgical | 1 | 1998 | 72 | 0.010 |
Why?
| Inulin | 1 | 1997 | 7 | 0.010 |
Why?
| Allopurinol | 1 | 1997 | 8 | 0.010 |
Why?
| Pentoxifylline | 1 | 1997 | 19 | 0.010 |
Why?
| Sodium | 1 | 1997 | 102 | 0.010 |
Why?
| Career Choice | 1 | 1998 | 116 | 0.010 |
Why?
| Arterial Occlusive Diseases | 1 | 1998 | 92 | 0.010 |
Why?
| Family | 1 | 1998 | 191 | 0.010 |
Why?
| Femoral Artery | 1 | 1998 | 122 | 0.010 |
Why?
| Cyclooxygenase 1 | 1 | 1996 | 5 | 0.010 |
Why?
| Constriction | 1 | 1996 | 9 | 0.010 |
Why?
| Immunoenzyme Techniques | 1 | 1996 | 165 | 0.010 |
Why?
| Isoenzymes | 1 | 1996 | 177 | 0.010 |
Why?
| Testosterone | 1 | 1996 | 119 | 0.010 |
Why?
| Vascular Surgical Procedures | 1 | 1998 | 178 | 0.010 |
Why?
| Cholecystitis | 1 | 1995 | 13 | 0.010 |
Why?
| Parenteral Nutrition | 1 | 1995 | 24 | 0.010 |
Why?
| Immunoblotting | 1 | 1995 | 134 | 0.010 |
Why?
| Estradiol | 1 | 1996 | 219 | 0.010 |
Why?
| Homeostasis | 1 | 1996 | 223 | 0.010 |
Why?
| Antibodies | 1 | 1995 | 178 | 0.010 |
Why?
| Membrane Proteins | 1 | 1996 | 389 | 0.010 |
Why?
| Rats, Inbred Strains | 1 | 1992 | 172 | 0.010 |
Why?
| Radiography | 1 | 1989 | 524 | 0.000 |
Why?
| Homosexuality | 1 | 1986 | 4 | 0.000 |
Why?
| Stomach Diseases | 1 | 1986 | 15 | 0.000 |
Why?
| Endoscopy | 1 | 1986 | 131 | 0.000 |
Why?
| Gastrointestinal Diseases | 1 | 1986 | 126 | 0.000 |
Why?
|
|
Turnage's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|